Ca030-001- A Phase 1/2 First-In-Human Study Of Bms-986249 Alone And In Combination With Nivolumab
Posted Date: Feb 26, 2020
- Investigator: Trisha Wise-Draper
- Specialties: Cancer, Oncology
- Type of Study: Drug
The main goal of this study is to characterize the safety, tolerability, and DLTs and to determine the MTD/RP2D of BMS-986249 administered as monotherapy and in combination with nivolumab in participants with advanced solid tumors.
Criteria:
To Be Eligible: Must Have Advanced Solid Tumor, Ecog 0-1, No Other Concurrent Active Malignancies Or Past Malignancies Within 2 Years, No Allergy To Study Treatments Or Components, No Uncontrolled Cardio Disease Or Active Infection
Keywords:
Phase 1, Advanced
For More Information:
Uc Cancer Center
513-5847698
cancer@uchealth.com